Feng Chi Biotech

Feng Chi Biotech EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Feng Chi Biotech (6744.TWO) as of Oct 30, 2026 is 13.85 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 16.12 M TWD — a change of -14.12% (lower).

EBITDA

13.85 MTWD

YoY

-14.12%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Feng Chi Biotech is 2025 13.85 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Feng Chi Biotech was 2024 16.12 M TWD. It decreases by -14.12% lower compared to the previous year.

The Feng Chi Biotech EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
18.72 M TWD
Jan 1, 2019
20.10 M TWD
Jan 1, 2020
28.58 M TWD
Jan 1, 2021
26.44 M TWD
Jan 1, 2022
27.07 M TWD
Jan 1, 2023
24.16 M TWD
Jan 1, 2024
16.12 M TWD
Jan 1, 2025
13.85 M TWD
The Feng Chi Biotech EBITDA history
YEAREBITDAYoY
13.85 MTWD-14.12%
16.12 MTWD-33.27%
24.16 MTWD-10.73%
27.07 MTWD+2.36%
26.44 MTWD-7.49%
28.58 MTWD+42.22%
20.10 MTWD+7.38%
18.72 MTWD+10.59%
16.93 MTWD+4.64%
16.17 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Feng Chi Biotech Stock analysis

What does Feng Chi Biotech do? Feng Chi Biotech Corp. generates revenue through the sale of prenatal and neonatal testing reagents and instruments, genetic testing analysis and development services, research instruments and reagents, and industrial microbiology and food testing reagents. The company's products are primarily sold to markets in Taiwan, China mainland, Japan, South Korea, Southeast Asia, and India, as well as other overseas regions. These services and products target healthcare providers, research institutions, and food safety regulators within these regions. The firm focuses on delivering comprehensive testing solutions across life science and microbiological applications for both clinical and industrial use cases. The company's product portfolio includes specialized reagents and instruments for prenatal and newborn screening, genetic analysis, and microbiological testing. These offerings are tailored to meet the needs of healthcare facilities and laboratories in the specified geographic markets. By providing end-to-end testing services and equipment, Feng Chi Biotech Corp. serves the growing demand for accurate diagnostic tools in reproductive health, genetic research, and food safety sectors. Feng Chi Biotech Corp. operates within the life science and microbiological testing services sector, offering a range of products that support prenatal care, neonatal screening, genetic research, and industrial food testing. The company's international sales strategy targets key regions in Asia, including Taiwan, China mainland, Japan, South Korea, Southeast Asia, and India, where healthcare and food safety regulations require regular testing. Their business model centers on providing reliable diagnostic solutions to medical and industrial clients across these markets. Feng Chi Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Feng Chi Biotech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Feng Chi Biotech is 13.85 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Feng Chi Biotech changed from 16.12 M TWD to 13.85 M TWD, representing a -14.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Feng Chi Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Feng Chi Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Feng Chi Biotech

All Key Metrics — Feng Chi Biotech